Combining inhibition of immune checkpoints and PARP: rationale and perspectives in cancer treatment-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Combining inhibition of immune checkpoints and PARP: rationale and perspectives in cancer treatment

Published:2022-11-02 Issue:11 Volume:26 Page:923-936
ISSN:1472-8222
Container-title:Expert Opinion on Therapeutic Targets
language:en
Short-container-title:Expert Opinion on Therapeutic Targets

Author:

Catalano Martina¹^ORCID,Francesco Iannone Luigi²,Cosso Federica¹,Generali Daniele³,Mini Enrico²,Roviello Giandomenico²

Affiliation:

1. School of Human Health Sciences, University of Florence, Florence, Italy

2. Department of Health Sciences, Section of Clinical Pharmacology and Oncology, University of Florence, Florence, Italy

3. Department of Medical, Surgery and Health Sciences, University of Trieste, Trieste, Italy

Publisher

Informa UK Limited

Subject

Clinical Biochemistry,Drug Discovery,Pharmacology,Molecular Medicine

Link

https://www.tandfonline.com/doi/pdf/10.1080/14728222.2022.2158813

Reference126 articles.

1. Biomarkers for Predicting Response to Immunotherapy with Immune Checkpoint Inhibitors in Cancer Patients

2. Development of Immunotherapy Combination Strategies in Cancer

3. An Overview of PARP Inhibitors for the Treatment of Breast Cancer

4. Use of PARP Inhibitors for Ovarian Cancer

5. PARP inhibition in treatment of pancreatic cancer

Cited by 7 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. New target therapies in prostate cancer: from radioligand therapy, to PARP-inhibitors and immunotherapy;The Quarterly Journal of Nuclear Medicine and Molecular Imaging;2024-06

2. Global research landscape and trends of cancer radiotherapy plus immunotherapy: A bibliometric analysis;Heliyon;2024-03

3. Precision Medicine in Castration-Resistant Prostate Cancer: Advances, Challenges, and the Landscape of PARPi Therapy—A Narrative Review;International Journal of Molecular Sciences;2024-02-11

4. Polyadenosine diphosphate-ribose polymerase inhibitors: advances, implications, and challenges in tumor radiotherapy sensitization;Frontiers in Oncology;2023-12-04

5. Personalized medicine for metastatic prostate cancer: The paradigm of PARP inhibitors;Critical Reviews in Oncology/Hematology;2023-12

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3